AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC

EIN: 136180380 501(c)(3) Diseases & Disorders

ALEXANDRIA, VA

Total Revenue
$174,337,293
Total Expenses
$155,488,043
Total Assets
$296,538,439
Net Assets
$183,846,488
🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Sign In — Free (10 views/day)

Financial Trends

Organization Details

Formation Year
1965
Legal Domicile
NY
Principal Officer
CLIFFORD HUDIS MD CEO
Phone
5714831300
Tax Period
2023-01-01 to 2023-12-31

AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC, founded in 1965, is a major nonprofit in the Diseases & Disorders sector that reported $174.3M in total revenue in fiscal year 2023. Revenue grew 19% year-over-year, indicating healthy expansion. Expenses of $155.5M left a modest 11% surplus.

Mission

:ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, AND PROMOTION OF THE HIGHEST QUALITY, EQUITABLE PATIENT CARE.

Program Service Accomplishments

Program 1
Expenses: $64,315,059 Revenue: $99,649,143

SEAN KHOZIN RECEIVED SEVERANCE IN THE AMOUNT OF $395,769 IN 2023.

Program 2
Expenses: $22,720,123 Revenue: $6,060,926

:QUALITY OF CARE INITIATIVES - CANCERLINQ, QUALITY MEASURES, GUIDELINES AND QOPI:QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI). A QUALITY SELF ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL...

Read more

:QUALITY OF CARE INITIATIVES - CANCERLINQ, QUALITY MEASURES, GUIDELINES AND QOPI:QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI). A QUALITY SELF ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES: QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICES TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. PRACTICES PARTICIPATE ANNUALLY AND OVER 263 PRATICES PARTICAPTED IN 2023.QUALITY TRAINING PROGRAM. ASCO'S QUALITY TRAINING PROGRAM IS DESIGNED TO EDUCATE AND TRAIN HEMATOLGY-ONOCOLOGY PRACTICE TEAMS, THE TECHNIQUES OF CLINICAL CARE AND OPERATIONAL PERFORMANCE QUALITY IMPROVEMENT. RECENT PARTICPANTS HAVE INCLUDED, BY INTENTIONAL RECRUITMENT, PRACTICES SERVING URBAN AND RURAL UNDERSERVED POPULATIONS ADRESSING HEALTH DISPARITY. 290 ONCOLOGY PROFESSIONALS RECEIVED TRAINING IN 2023.GUIDELINES:A CRITICAL COMPONENT OF THE SOCIETY'S QUALITY EFFORTS, THE ASCO GUIDELINES PROGRAM ACTIVELY ENGAGES WITH MORE THAN 1,000 ASCO MEMBER VOLUNTEERS, ON A YEARLY BASIS, TO DEVELOP EVIDENCE AND EXPERT-DRIVEN RECOMMENDATIONS THAT INFORM HIGH-QUALITY AND EQUITABLE CANCER CARE WORLDWIDE. ASCO'S GUIDELINES PROGRAM WHICH INCLUDES TRADITIONAL AS WELL AS LIVING CLINICAL PRACTICE GUIDELINES, UPDATES, AND ORGANIZATIONAL STANDARDS, FOCUSES ON CONTENT AREAS WITH IDENTIFIED KNOWLEDGE GAPS, HIGH UNCERTAINTY, OR UNMET AND PRESSING CLINICAL NEEDS FACING ONCOLOGY CARE TEAMS IN CLINICAL PRACTICE. ASCO'S GUIDELINES RESOURCES ARE DESIGNED TO PROMOTE GUIDELINE-CONCORDANT CANCER CARE AT THE CLINICIAN, CAREGIVER, AND PATIENT LEVEL. FOR PATIENTS AND CAREGIVERS, COMPLEX GUIDELINE INFORMATION IS DISTILLED AND PRESENTED IN A USER-FRIENDLY FORMAT THROUGH ASCO'S CANCER.NET. FOR CLINICIANS, THESE TOOLS ARE OFFERED THROUGH CONCISE PRACTICE-FACING COMPANION ARTICLES, SUMMARY RECOMMENDATION TABLES, ALGORITHMS, PODCASTS, VISUAL ABSTRACTS, AND OTHER RESOURCES THAT ARE ACCESSIBLE THROUGH ASCO JOURNALS, THE ASCO WEBSITE, AND THE ASCO GUIDELINES APP.PUBLISHED AS A REGULAR, AND OFTEN MOST READ, FEATURE IN THE JOURNAL OF CLINICAL ONCOLOGY (JCO) WITH OVER 1.3 MILLION DOWNLOADS IN 2023, GUIDELINES ALSO SERVE AS THE EVIDENCE FOUNDATION FOR ASCO'S MEMBER EDUCATION, PATIENT EDUCATION, POLICY, CARE DELIVERY, AND QUALITY EFFORTS, ALL WITH THE GOAL OF CANCER TREATMENT AND CARE INFORMED BY THE HIGHEST QUALITY EVIDENCE AND EXPERT INTERPRETATION, INTEGRATED INTO GLOBAL PRACTICE AT THE POINT OF PATIENT CARE. ASCO TYPICALLY ENGAGES 30-40 GUIDELINE EXPERT PANELS AT ANY GIVEN TIME AND PUBLISHES BETWEEN 20-25 NEW OR UPDATED GUIDELINES EACH YEAR; WITH A GROWING LIBRARY OF GUIDELINE SUMMARIES THAT HAVE BEEN TRANSLATED INTO SPANISH. TWENTY-THREE GUIDELINE PRODUCTS WERE PUBLISHED IN THE JCO IN 2023, INCLUDING SEVERAL RAPID UPDATES AND MULTIPLE ITERATIONS OF ASCO'S COMPREHENSIVE LIVING GUIDELINE ADDRESSING THE CARE OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER. IN ADDITION, 13 COMPANION ARTICLES PROVIDING GUIDELINE CLINICAL INSIGHTS WERE PUBLISHED IN THE JCO ONCOLOGY PRACTICE.

Program 3
Expenses: $9,157,287 Revenue: $4,332,922

:RESEARCH INITIATIVES - TAPUR/CENTRA:ASCO'S CENTER FOR RESEARCH AND ANALYTICS LEADS ASCO'S RESEARCH EFFORTS, INCLUDING ITS CLINICAL CANCER RESEARCH PROGRAMS. MAJOR PROGRAMS AND PROJECTS INCLUDE: (1)...

Read more

:RESEARCH INITIATIVES - TAPUR/CENTRA:ASCO'S CENTER FOR RESEARCH AND ANALYTICS LEADS ASCO'S RESEARCH EFFORTS, INCLUDING ITS CLINICAL CANCER RESEARCH PROGRAMS. MAJOR PROGRAMS AND PROJECTS INCLUDE: (1) THE TARGETED AGENT AND PROFILING UTILIZATION REGISTRY WHICH IS PRECISION MEDICINE BASKET TRIAL INVESTIGATING THE EFFICACY OF MORE THAN 15 DIFFERENT ANTI-CANCER TARGETED AGENTS IN PATIENTS WITH ADVANCED CANCERS AND HAS ENROLLED ALMOST THAN 3,000 PATIENTS SINCE IT OPENED IN 2016 AND CONTINUES TO PUBLISH TRIAL RESULTS IN PEER-REVIEWED CLINICAL CANCER RESEARCH JOURNALS AND PRESENT RESULTS AT CLINICAL CANCER RESEARCH CONFERENCES; (2) ASCO'S COVID-19 REGISTRY WHICH INCLUDES A DATABASE OF OVER 6,000 PATIENTS WITH CANCER AND COVID-19 FROM 2020 TO 2022 AND RESEARCH ON THE DATABASE BY CENTRA STAFF AND MADE AVAILABLE TO EXTERNAL RESEARCHERS (THE REGISTRY CLOSED TO DATA COLLECTION AT THE END OF 2023 ALTHOUGH DATA IS STILL AVAILABLE FOR USE); (3) ASCO'S MEMBER RESEARCH SURVEY POOL, WHICH FACILITATES RESEARCH OF CANCER CARE PROVIDERS BY DISSEMINATING SURVEYS FROM MERITORIOUS SURVEY RESEARCH PROJECTS TO ASCO MEMBERS WHO HAVE AGREED TO BE A PART OF THE SURVEY POOL; (4) THE STATE OF CANCER CARE IN AMERICA PROGRAM, WHICH ASSESSES AND REPORTS ON AND REPORT ON THE STATE OF AND CHANGES IN CANCER CARE IN THE US; (5) ASCO'S WORK IN IMPROVING ACCESS TO CLINICAL TRIALS THROUGH TRAINING FOR SITES AND WORKING TO COMBAT BARRIERS TO ENROLLMENT FOR UNDER-REPRESENTED POPULATIONS OF PATIENTS; AND (6) THE START-UP FOR A NEW CLINICAL RESEARCH STUDY, THE CDK4/6 INHIBITOR DOSING STUDY, WHICH WILL OPEN TO ENROLLMENT IN 2024 AND EVALUATES STANDARD VS. TITRATED DOSING APPROACHES FOR PATIENTS AGE 65 AND OLDER WITH HR+/HER2- METASTATIC BREAST CANCER. CENTRA ALSO SUPPORTS WORKSHOPS, MEETINGS, AND RESEARCH PROJECTS WITH OTHER STAKEHOLDERS IN CANCER RESEARCH, INCLUDING THE NCI, THE FDA'S ONCOLOGY CENTER FOR EXCELLENCE, AND OTHER NON-PROFIT GROUPS, SUCH AS THE FRIENDS OF CANCER RESEARCH.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Sign In — Free (10 views/day)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $16,259,283
Program Service Revenue $127,986,242
Investment Income $23,661,513
Other Revenue $6,430,255
TOTAL REVENUE $174,337,293

Expense Breakdown

Grants Paid $4,632,496
Salaries & Benefits $70,278,616
Fundraising Expenses $0
Program Expenses $124,719,334
Other Expenses $80,576,931
TOTAL EXPENSES $155,488,043

Year-over-Year Comparison

2023 2022 Change
Revenue $174,337,293 $146,139,860 +0.2%
Expenses $155,488,043 $144,269,886 +0.1%
Net Income $18,849,250 $1,869,974 +9.1%
Key Indicators
Grants to Organizations Grants to Individuals Lobbying Political Activity Foreign Activities Donor Advised Fund Schedule B Required
🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Sign In

Governance

Voting Members
18
Independent Members
18
Employees
520
Volunteers
4125

Governance Policies

Conflict of Interest Policy
Whistleblower Policy
Document Retention Policy

Special Practices & Reported Activities

Operated a School
Operated a Hospital
Provided First Class Travel
Reported Conflict of Interest
Reported Asset Diversion
Excess Benefit Transaction
Made Political Expenditures
Engaged in Lobbying
Operated Donor Advised Fund
Maintained Art Collections
Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers
11
$2,334,416
Total Directors
22
$0
Key Employees
8
$3,910,826
Highest Compensated
5
reported
Name Title Hours/Week Role Reportable Comp Other Comp Total
EVERETT E VOKES MD CHAIR/PAST PRESIDENT 1.00
Officer Director
$0 $0 $0
ERIC P WINER MD PRESIDENT/CHAIR 1.00
Officer Director
$0 $0 $0
LYNN M SCHUCHTER MD PRESIDENT-ELECT/PRESIDENT 1.00
Officer Director
$0 $0 $0
ROBIN ZON MD PRESIDENT-ELECT 1.00
Officer Director
$0 $0 $0
LORI J PIERCE MD PAST PRESIDENT (PARTIAL YEAR) 1.00
Officer Director
$0 $0 $0
ELIZABETH A MITTENDORF MD PHD MHC TREASURER (PARTIAL YEAR) 1.00
Officer Director
$0 $0 $0
ELIZABETH R PLIMACK MD MS TREASURER-ELECT/TREASURER 1.00
Officer Director
$0 $0 $0
TAOFEEK K OWONIKOKO MD PHD TREASURER-ELECT 1.00
Officer Director
$0 $0 $0
FREDRICK CHITE ASIRWA MD MBCHB BOARD MEMBER 1.00
Director
$0 $0 $0
ETHAN M BASCH MD MSC BOARD MEMBER (PARTIAL YEAR) 1.00
Director
$0 $0 $0
LISA A CAREY MD BOARD MEMBER 1.00
Director
$0 $0 $0
MARIANA CHAVEZ MACGREGOR MD MSC BOARD MEMBER 1.00
Director
$0 $0 $0
TARA O HENDERSON MD MPH BOARD MEMBER 1.00
Director
$0 $0 $0
CAROLYN B HENDRICKS MD BOARD MEMBER 1.00
Director
$0 $0 $0
KATHLEEN N MOORE MD MS BOARD MEMBER (PARTIAL YEAR) 1.00
Director
$0 $0 $0
ANN H PARTRIDGE MD MPH BOARD MEMBER 1.00
Director
$0 $0 $0
DEBRA PATT MD PHD BOARD MEMBER (PARTIAL YEAR) 1.00
Director
$0 $0 $0
ENRIQUE SOTO PEREZ DE CELIS MD MSC BOARD MEMBER 1.00
Director
$0 $0 $0
GLADYS I RODRIGUEZ MD BOARD MEMBER 1.00
Director
$0 $0 $0
JENNIFER TEMEL MD BOARD MEMBER 1.00
Director
$0 $0 $0
MICHAEL A THOMPSON MD PHD BOARD MEMBER (PARTIAL YEAR) 1.00
Director
$0 $0 $0
KAREN M WINKFIELD MD PHD BOARD MEMBER 1.00
Director
$0 $0 $0
CLIFFORD A HUDIS MD CEO 30.00
Officer
$1,060,801 $24,750 $1,085,551
DINA MICHELS ESQ SECRETARY, EVP & COO 37.50
Officer
$685,749 $42,792 $728,541
LINDA JENSEN EVP & CFO 30.00
Officer
$477,532 $42,792 $520,324
JULIE R GRALOW MD EVP & CMO 37.50
Key Emp
$632,400 $42,792 $675,192
NANCY DALY MS MPH EVP & CONQUER CANCER CEO 1.00
Key Emp
$516,637 $42,677 $559,314
CARMEN JACKSON CEO - CLQ 37.50
Key Emp
$515,125 $49,419 $564,544
CHRISTOPHER MERLAN EVP & CHIEF DIGITAL OFFICE 37.50
Key Emp
$475,728 $44,731 $520,459
JAMIE VON ROENN MD MED VP, EDU., SCIENCE & PROF. 37.50
Key Emp
$457,512 $33,834 $491,346
AMANDA DAVIS-AITKEN VICE PRESIDENT, MEETING SV 37.50
Key Emp
$338,635 $33,749 $372,384
ANGELA COCHRAN VP, PUBLISHING 37.50
Key Emp
$336,979 $40,401 $377,380
BARTON LAWYER VICE PRESIDENT - IT 37.50
Key Emp
$303,038 $47,169 $350,207
STEPHEN GRUBBS MD VP, CARE DELIVERY 37.50
Highest
$445,051 $42,606 $487,657
KRISTEN NEESE CHIEF MARKETING & COMMUNICATIONS OFFICER 37.50
Highest
$363,368 $44,731 $408,099
PAULA KING CHIEF HUMAN RESOURCES OFFICER 37.50
Highest
$362,762 $44,731 $407,493
DEBORAH KAMIN PHD VP, POLICY/ADVOCACY 30.00
Highest
$356,959 $42,677 $399,636
MELISSA TAI VP, CEIL & GENERAL COUNSEL 29.50
Highest
$350,115 $49,281 $399,396
SEAN KHOZIN MD FORMER CLQ CEO 37.50
$395,769 $0 $395,769
Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year Revenue Expenses Assets Net Income
2024 No data No data No data No data
2023 $174,337,293 $155,488,043 $296,538,439 $18,849,250
2022 $146,139,860 $144,269,886 $251,452,025 $1,869,974
2021 $107,588,628 $119,778,637 $283,820,689 $-12,190,009
2020 $138,374,082 $134,735,801 $279,249,289 $3,638,281
2019 $162,711,421 $148,108,869 $269,484,782 $14,602,552
2018 $159,884,094 $145,806,474 $227,652,015 $14,077,620
Explore More Nonprofits
Top 100 Nonprofits in Virginia Largest U.S. Nonprofits Best Rated Nonprofits Most Efficient Nonprofits

Compare AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC with other nonprofits in Virginia and across the country.